Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

OBJECTIVES: Both TNF inhibitors (TNFi) and rituximab (RTX), a B-cell depleting biologic, can disrupt the immune system in RA. RTX is licensed in Europe for use following TNFi failure. However, safety data on serious infections (SIs) are scarce for RTX in daily practice. This analysis aims to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Fernández, Lucía, De Cock, Diederik, Lunt, Mark, Low, Audrey S, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105920/
https://www.ncbi.nlm.nih.gov/pubmed/28968862
http://dx.doi.org/10.1093/rheumatology/kex304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105920/
https://www.ncbi.nlm.nih.gov/pubmed/28968862
http://dx.doi.org/10.1093/rheumatology/kex304

Ejemplares similares